- Multiparametric magnetic resonance imaging (mpMRI) offers a cost-effective triage solution that improves diagnosis of clinically significant (cs) prostate cancer (PCa) while reducing unnecessary biopsies and overtreatment of insignificant PCa.
Why this matters
- The traditional diagnostic approach, systematic transrectal ultrasound-guided prostate biopsy, is invasive, has a false-negative rate of >40%, and leads to overdiagnosis of low-grade, insignificant PCa.
- Researchers analyzed the health records of 653 consecutive patients with suspected PCa who underwent mpMRI at a large public tertiary referral training hospital:
- Age: median, 65 (interquartile range, 58-70) years.
- PSA: median, 6.8 (interquartile range, 4.6-9.6) ng/mL.
- Prostate volume: median, 52 (interquartile range, 45-75) mL.
- PSA density: median, 0.12 (interquartile range, 0.08–0.20).
- Funding: None.
- PCa was diagnosed in 240 patients (69.8%).
- csPCa was diagnosed in 208 patients (60.5%).
- Higher rates of csPCa were observed for higher Prostate Imaging Reporting and Data System scores.
- mpMRI resulted in a 47.3% biopsy avoidance rate.
- The study was retrospective and subject to patient selection bias.